Alejandra Gurtman, M.D., is Senior Vice President Pfizer Vaccine Clinical Research and Development, and is leading the clinical development of Pfizer’s vaccine pipeline including the mRNA vaccine platform. She has provided oversight and leadership for the Respiratory Syncytial Virus vaccine program that recently resulted in approval of both RSV adult and maternal indications in the US and Europe. Alejandra joined the Vaccine Research and Development group in 2005 and has over 30 years of clinical research experience.  She was a critical member of Pfizer’s COVID 19 vaccine program supporting all aspects of development and strategy. She was instrumental in bringing the adolescent and pediatric program forward for Emergency Use Authorization.

Before this role, she was the Global Clinical Lead for the Staphylococcus aureus vaccine (SA4Ag) and prior to that, she led the Prevnar 13 Pediatric Program through all phases of development.  She also provided significant strategic and tactical support to the Prevnar 13 Adult Program and studies performed in high-risk immunocompromised children and adults.

Alejandra received her medical school and internal medicine training at the University of Buenos Aires, School of Medicine, Argentina, and postdoctoral training as fellow and chief fellow of infectious diseases at Mount Sinai School of Medicine, New York.  She served on the faculty of the Mount Sinai School of Medicine as Associate Professor.  In her academic role she gained experience in conduct of clinical trials, care of high-risk populations, and was the founder and director of the Mount Sinai travel medicine program.  

Dr. Gurtman is the author/co-author on 100 original research articles and book chapters.